MEDIA WATCH: Viagra faces slew of healthy competitors

It has been a busy year for Pfizer, the maker of the ubiquitous erectile-dysfunction treatment, Viagra. The company spent the fifth birthday of its banner pill combating the first rivals to its worldwide monopoly. Bayer AG/GlaxoSmithKline's Levitra and Icos/Eli Lilly's Cialis have already started snatching up international market share (the latter awaits approval in the US). The coverage suggests that erectile dysfunction has a significantly bigger market than Viagra has tapped.

It has been a busy year for Pfizer, the maker of the ubiquitous erectile-dysfunction treatment, Viagra. The company spent the fifth birthday of its banner pill combating the first rivals to its worldwide monopoly. Bayer AG/GlaxoSmithKline's Levitra and Icos/Eli Lilly's Cialis have already started snatching up international market share (the latter awaits approval in the US). The coverage suggests that erectile dysfunction has a significantly bigger market than Viagra has tapped.

Most frequent messages 1. Viagra's five-year dominance faces serious competition 2. Viagra hasn't helped all erectile dysfunction sufferers. As such, something else will 3. So far, no serious side-effects have been reported for the three drugs 4. Treatment users are eager to see medication alternatives that suit their lifestyle 5. Studies abound on which drugs are safest and best. More independent research would help Based on 30 articles from major US and European publications appearing Sept. 19-Nov. 19, 2003. Evaluation and analysis by Biz360.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.